MedTrace Logo

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

NCT02852005 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-08-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the AIDSVAX B/E vaccine and the MVA/HIV62B vaccine in healthy, HIV-1-uninfected adults who previously received MVA/HIV62B in DNA/MVA or MVA/MVA vaccine regimens in the HVTN 205 study.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

MVA/HIV62B vaccine

1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid

BIOLOGICAL

AIDSVAX B/E vaccine

600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid

BIOLOGICAL

Placebo

Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Paul Goepfert · University of Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-08-29
Completion
2019-10-29
FDA Drug
Yes

Countries

  • United States
  • Peru

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02852005 on ClinicalTrials.gov